152 related articles for article (PubMed ID: 22302350)
21. Changes in PIK3CA mutation status are not associated with recurrence, metastatic disease or progression in endocrine-treated breast cancer.
Arthur LM; Turnbull AK; Renshaw L; Keys J; Thomas JS; Wilson TR; Lackner MR; Sims AH; Dixon JM
Breast Cancer Res Treat; 2014 Aug; 147(1):211-9. PubMed ID: 25104442
[TBL] [Abstract][Full Text] [Related]
22. PIK3CA alterations in Middle Eastern ovarian cancers.
Abubaker J; Bavi P; Al-Haqawi W; Jehan Z; Munkarah A; Uddin S; Al-Kuraya KS
Mol Cancer; 2009 Jul; 8():51. PubMed ID: 19638206
[TBL] [Abstract][Full Text] [Related]
23. Genomic analyses reveal mutational signatures and frequently altered genes in esophageal squamous cell carcinoma.
Zhang L; Zhou Y; Cheng C; Cui H; Cheng L; Kong P; Wang J; Li Y; Chen W; Song B; Wang F; Jia Z; Li L; Li Y; Yang B; Liu J; Shi R; Bi Y; Zhang Y; Wang J; Zhao Z; Hu X; Yang J; Li H; Gao Z; Chen G; Huang X; Yang X; Wan S; Chen C; Li B; Tan Y; Chen L; He M; Xie S; Li X; Zhuang X; Wang M; Xia Z; Luo L; Ma J; Dong B; Zhao J; Song Y; Ou Y; Li E; Xu L; Wang J; Xi Y; Li G; Xu E; Liang J; Yang X; Guo J; Chen X; Zhang Y; Li Q; Liu L; Li Y; Zhang X; Yang H; Lin D; Cheng X; Guo Y; Wang J; Zhan Q; Cui Y
Am J Hum Genet; 2015 Apr; 96(4):597-611. PubMed ID: 25839328
[TBL] [Abstract][Full Text] [Related]
24. Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
Toomey S; Eustace AJ; Fay J; Sheehan KM; Carr A; Milewska M; Madden SF; Teiserskiene A; Kay EW; O'Donovan N; Gallagher W; Grogan L; Breathnach O; Walshe J; Kelly C; Moulton B; Kennedy MJ; Gullo G; Hill AD; Power C; Duke D; Hambly N; Crown J; Hennessy BT
Breast Cancer Res; 2017 Jul; 19(1):87. PubMed ID: 28750640
[TBL] [Abstract][Full Text] [Related]
25. PIK3CA mutational status in circulating tumor cells can change during disease recurrence or progression in patients with breast cancer.
Markou A; Farkona S; Schiza C; Efstathiou T; Kounelis S; Malamos N; Georgoulias V; Lianidou E
Clin Cancer Res; 2014 Nov; 20(22):5823-34. PubMed ID: 25398847
[TBL] [Abstract][Full Text] [Related]
26. Improving the Performance of Somatic Mutation Identification by Recovering Circulating Tumor DNA Mutations.
Fu Y; Jovelet C; Filleron T; Pedrero M; Motté N; Boursin Y; Luo Y; Massard C; Campone M; Levy C; Diéras V; Bachelot T; Garrabey J; Soria JC; Lacroix L; André F; Lefebvre C
Cancer Res; 2016 Oct; 76(20):5954-5961. PubMed ID: 27535334
[TBL] [Abstract][Full Text] [Related]
27. Novel mutations of PIK3CA gene in head and neck squamous cell carcinoma.
Al-Amri AM; Vatte C; Cyrus C; Chathoth S; Hashim TM; Mohamed YS; Al Ali R; Alsaid A; Al Ali A
Cancer Biomark; 2016; 16(3):377-83. PubMed ID: 26889984
[TBL] [Abstract][Full Text] [Related]
28. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma.
Saal LH; Holm K; Maurer M; Memeo L; Su T; Wang X; Yu JS; Malmström PO; Mansukhani M; Enoksson J; Hibshoosh H; Borg A; Parsons R
Cancer Res; 2005 Apr; 65(7):2554-9. PubMed ID: 15805248
[TBL] [Abstract][Full Text] [Related]
29. Effects of mutations in Wnt/β-catenin, hedgehog, Notch and PI3K pathways on GSK-3 activity-Diverse effects on cell growth, metabolism and cancer.
McCubrey JA; Rakus D; Gizak A; Steelman LS; Abrams SL; Lertpiriyapong K; Fitzgerald TL; Yang LV; Montalto G; Cervello M; Libra M; Nicoletti F; Scalisi A; Torino F; Fenga C; Neri LM; Marmiroli S; Cocco L; Martelli AM
Biochim Biophys Acta; 2016 Dec; 1863(12):2942-2976. PubMed ID: 27612668
[TBL] [Abstract][Full Text] [Related]
30. Mucinous breast carcinomas lack PIK3CA and AKT1 mutations.
Kehr EL; Jorns JM; Ang D; Warrick A; Neff T; Degnin M; Lewis R; Beadling C; Corless CL; Troxell ML
Hum Pathol; 2012 Dec; 43(12):2207-12. PubMed ID: 22705004
[TBL] [Abstract][Full Text] [Related]
31. Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer.
Chandarlapaty S; Sakr RA; Giri D; Patil S; Heguy A; Morrow M; Modi S; Norton L; Rosen N; Hudis C; King TA
Clin Cancer Res; 2012 Dec; 18(24):6784-91. PubMed ID: 23092874
[TBL] [Abstract][Full Text] [Related]
32. Mutations in PIK3CA are infrequent in neuroblastoma.
Dam V; Morgan BT; Mazanek P; Hogarty MD
BMC Cancer; 2006 Jul; 6():177. PubMed ID: 16822308
[TBL] [Abstract][Full Text] [Related]
33. Targeted next-generation sequencing for molecular diagnosis of endometriosis-associated ovarian cancer.
Er TK; Su YF; Wu CC; Chen CC; Wang J; Hsieh TH; Herreros-Villanueva M; Chen WT; Chen YT; Liu TC; Chen HS; Tsai EM
J Mol Med (Berl); 2016 Jul; 94(7):835-47. PubMed ID: 26920370
[TBL] [Abstract][Full Text] [Related]
34. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.
Stemke-Hale K; Gonzalez-Angulo AM; Lluch A; Neve RM; Kuo WL; Davies M; Carey M; Hu Z; Guan Y; Sahin A; Symmans WF; Pusztai L; Nolden LK; Horlings H; Berns K; Hung MC; van de Vijver MJ; Valero V; Gray JW; Bernards R; Mills GB; Hennessy BT
Cancer Res; 2008 Aug; 68(15):6084-91. PubMed ID: 18676830
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of TP53/PIK3CA mutations using texture and morphology analysis on breast MRI.
Moon WK; Chen HH; Shin SU; Han W; Chang RF
Magn Reson Imaging; 2019 Nov; 63():60-69. PubMed ID: 31425802
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of PIK3CA mutations as a biomarker in Chinese breast carcinomas from Western China.
Cheng J; Fu S; Wei C; Tania M; Khan MA; Imani S; Zhou B; Chen H; Xiao X; Wu J; Fu J
Cancer Biomark; 2017; 19(1):85-92. PubMed ID: 28269754
[TBL] [Abstract][Full Text] [Related]
37. Phosphatidylinositol 3-kinase (PI3KCA) oncogene mutation analysis and gene expression profiling in primary breast cancer patients.
Kandula M; Chennaboina KK; Ys AR; Raju S
Asian Pac J Cancer Prev; 2013; 14(9):5067-72. PubMed ID: 24175777
[TBL] [Abstract][Full Text] [Related]
38. PIK3CA mutations in in situ and invasive breast carcinomas.
Miron A; Varadi M; Carrasco D; Li H; Luongo L; Kim HJ; Park SY; Cho EY; Lewis G; Kehoe S; Iglehart JD; Dillon D; Allred DC; Macconaill L; Gelman R; Polyak K
Cancer Res; 2010 Jul; 70(14):5674-8. PubMed ID: 20551053
[TBL] [Abstract][Full Text] [Related]
39. [Clinical, diagnostic significance and theranostic interest of PIK3CA gene mutations in breast cancer].
Harlé A; Lion M; Lozano N; Merlin JL
Bull Cancer; 2013 Oct; 100(10):947-54. PubMed ID: 24077110
[TBL] [Abstract][Full Text] [Related]
40. Analysis of PIK3CA mutations in breast cancer subtypes.
Arsenic R; Lehmann A; Budczies J; Koch I; Prinzler J; Kleine-Tebbe A; Schewe C; Loibl S; Dietel M; Denkert C
Appl Immunohistochem Mol Morphol; 2014 Jan; 22(1):50-6. PubMed ID: 24471188
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
